✦ LIBER ✦

444 Quasispecies evolution in chronic hepatitis C patients after immunization with the therapeutic vaccine IC41

✍ Scribed by C. Sarrazin; A. Wohnsland; H. Wedemeyer; V. Bürger; W. Zauner; E. Tauber; C.S. Kladei

Book ID: 117374722
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 134 KB
Volume: 44
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(06)80444-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapeutic Vaccination of Chronic Hepat

Therapeutic Vaccination of Chronic Hepatitis C Nonresponder Patients With the Peptide Vaccine IC41

✍ Christoph S. Klade; Heiner Wedemeyer; Thomas Berg; Holger Hinrichsen; Grazyna Ch 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 980 KB

Therapeutic vaccine IC41 as late add-on

Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C

✍ Heiner Wedemeyer; Elisabeth Schuller; Verena Schlaphoff; Rudolf E. Stauber; Joha 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 768 KB

19 Induction of TH1/TC1 type immunity in

19 Induction of TH1/TC1 type immunity in chronic hepatitis C non-responder patients with the therapeutic peptide vaccine IC41

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 257 KB

Open-label trial of therapeutic immuniza

Open-label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C

✍ Dendev Batdelger; Dorjiin Dandii; Vichai Jirathitikal; Aldar S. Bourinbaiar 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Antifibrotic activity correlates with im

Antifibrotic activity correlates with immune response to E1 therapeutic vaccination in 24 patients with chronic active hepatitis C

✍ F. Nevens; T. Roskams; H. Van Vlierberghe; Y. Horsmans; D. Sprengers; A. Elewaut 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 284 KB

Immunization with a DNA vaccine candidat

Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination

✍ Marlen Castellanos; Zurina Cinza; Zaily Dorta; Gloria Veliz; Héctor Vega; Irma L 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

## Abstract ## Background In the present study, we evaluated the safety of CIGB‐230, a novel vaccine candidate based on the mixture of a plasmid for DNA immunization, expressing hepatitis C virus (HCV) structural antigens, with a recombinant HCV Core protein. ## Methods Fifteen HCV chronically‐i